June 20 (Reuters) - Novimmune SA IPO-NOVI.S:
* TG THERAPEUTICS AND NOVIMMUNE SA ANNOUNCE GLOBAL AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF A NOVEL ANTI-CD47/ ANTI-CD19 BISPECIFIC ANTIBODY
* TG THERAPEUTICS INC - COMPANIES WILL JOINTLY DEVELOP PRODUCT ON A WORLDWIDE BASIS, FOCUSING ON INDICATIONS IN AREA OF HEMATOLOGIC B-CELL MALIGNANCIES
* TG THERAPEUTICS - CLINICAL TRIALS ON TG-1801 ARE EXPECTED TO COMMENCE LATER THIS YEAR OR EARLY IN 2019
* TG THERAPEUTICS - TO MAKE UP-FRONT & MILESTONES PAYMENTS BASED ON EARLY CLINICAL DEVELOPMENT
* TG THERAPEUTICS - TO BE RESPONSIBLE FOR COSTS OF CLINICAL DEVELOPMENT OF PRODUCTS THROUGH END OF PHASE II Source text for Eikon: Further company coverage:
